SEFH’s Hemoderivatives Workgroup (GEMEH)’s mission shall be as follows:
1-To collaborate and promote the development, update and implementation of effective and safe clinical practices regarding the use of hemoderivative drugs, based on the most recent scientific evidence, and to build consensus and prepare clinical guidelines in connection with hemoderivative drugs.
2-To strengthen the importance of the key aspects for the management of hemoderivative drugs, such as traceability and proper handling and storage.
3-To advise hospital pharmacists and other health professionals on the proper pharmacotherapy and follow-up of conditions amenable to treatment with hemoderivatives, among other therapeutic alternatives. To establish the role of pharmacists in the treatment of conditions traditionally managed with hemoderivatives (hemorrhages, coagulopathies, etc.), particularly those where new drugs and advanced therapies are being developed to optimize treatment.
4-To promote an effective use of hemoderivative drugs and contribute to the definition of decision-making criteria.
5-To establish an collaborate in the development of strategies to improve adherence to hemoderivative-based therapies as a key factor to improve health outcomes. To promote the use of e-health tools in this regard.
6-To expand hospital pharmacists’ understanding on the properties and effects of the different hemoderivative drug classes: albumin, immunoglobulins, coagulation factors, prothrombin complex, etc. To promote and contribute to the conduct of observational research projects geared towards a better understanding of the use of such medicines. To promote and facilitate the conduct of clinical trials aimed at evaluating the efficacy and safety of hemoderivatives in areas where there is uncertainty about their real therapeutic value.
7-To promote and facilitate the conduct of pharmacoeconomic and health outcome studies, with a view to gauging the real impact of hemoderivatives in terms of cost and outcomes, across the different therapies for each condition.
8-To contribute to training hospital pharmacists in the characteristics of hemoderivative drugs, as well as in their proper management, use, therapeutic positioning, pharmacotherapeutic follow-up, conservation, traceability and administration. To promote courses and continuous training programs for both SEFH members and other professionals.
9-To advise such centers and institutions as may require it on the appropriate management of hemoderivatives and, if appropriate, provide them with the required training.
10-To foster the use of the new technologies to provide hospital pharmacists with an enhanced access to evidence-based information on the use of hemoderivative drugs.